Long-term survival following oesophagectomy has doubled from 25% to 50% in the last 30 years. The LASER cohort study found that 67% of oesophageal cancer survivors suffer from long-term GI symptoms affecting quality of life. Anatomical changes during oesophagectomy are associated with gut microbiome dysbiosis. Small intestinal bacterial overgrowth (SIBO) is diagnosed using hydrogen and methane breath tests but remains poorly understood. This study uses a multi-omic approach to improve understanding of microbiome-derived metabolic pathways.
Aims
Methods
Multicentre, cross-sectional study of 100 disease-free patients more than 1 year after oesophagectomy. Patients provide stool, saliva, urine and breath samples after a minimum 4-hour fast. Metagenomic sequencing on saliva and stool (Illumina HiSeq). Metabonomic analysis via NMR and UPLC-MS. Volatolomic analysis using mid-polar, polar and 2D GC-MS-TOF on breath, saliva, blood, urine, and stool samples.
Recruitment to this trial takes place through participating NHS centres. If you think you may be eligible, please speak with your GP or hospital clinician who can refer you through the appropriate pathway.
Healthcare professional enquiries: Munir Tarazi